FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384663359> ?p ?o ?g. }

• W4384663359 endingPage "1326" @default.
• W4384663359 startingPage "1314" @default.
• W4384663359 abstract "Melatonin is effective for migraine prevention in adults. We hypothesized that melatonin would also be effective for migraine prevention in children and adolescents.This was a randomized, double-blind trial of melatonin (3 mg or 6 mg) versus placebo for migraine prevention in 10-17 year-olds with 4-28/28 headache days at baseline. Participants were recruited from the UCSF Child & Adolescent Headache Program, UCSF child neurology clinic, and social media advertisements. Migraine diagnosis was confirmed by a headache specialist. Participants completed an 8-week single-blind placebo run-in. Those meeting randomization criteria (≥4 headache days and ≥23/28 electronic diary entries during weeks 5-8) were randomized 1:1:1 to placebo:melatonin 3 mg:melatonin 6 mg nightly for 8 weeks. The primary outcome measure was migraine days in weeks 5-8 of randomized treatment between melatonin (combined 6 mg + 3 mg) versus placebo. We aimed to enroll n = 210.The study closed early due to slow enrollment (n = 72). Two participants were in the single-blind phase when the study closed, therefore the meaningful n = 70. Sixteen percent (11/70) were lost to follow-up during the single-blind phase. An additional 21% (15/70) did not meet randomization criteria (<4 headache days: n = 5, <23/28 diary days: n = 7, both: n = 3). Sixty-three percent (44/70) were eligible to randomize, of whom 42 randomized (n = 14 per arm). Taking another preventive at enrollment (OR 8.3, 95% CI 1.01 to 68.9) was the only variable associated with meeting randomization criteria. Of those randomized, 91% (38/42) provided diary data in the final 4-weeks. However, given the amount of missing data, only those with ≥21/28 diary days were analyzed-7/14 (50%) in the placebo group, and 20/28 (71%) in the melatonin groups combined. Median (IQR) migraine/migrainous days in weeks 5-8 of double-blind treatment was 2 (1-7) in the placebo group versus 2 (1-12) in the melatonin groups combined; the difference in medians (95% CI for the difference) was 0 days (-9 to 3). There were no differences in adverse events between groups.When compared to recall at enrollment, headache days decreased across the single-blind placebo phase and the double-blind phase. There was no suggestion of superiority of melatonin; however, given the substantial portion of missing data, numerically higher in the placebo arm, and underpowering, this should not be interpreted as proof of inefficacy. Melatonin was generally well tolerated with no serious adverse events. Future migraine preventive trials in this age group may find this trial helpful for anticipating enrollment needs if using a single-blind placebo run-in. Enriching for those already on a migraine preventive may improve randomization rates in future trials, though would change the generalizability of results." @default.
• W4384663359 created "2023-07-20" @default.
• W4384663359 creator A5003163742 @default.
• W4384663359 creator A5032639003 @default.
• W4384663359 creator A5034447689 @default.
• W4384663359 creator A5042770203 @default.
• W4384663359 creator A5052408475 @default.
• W4384663359 creator A5059512015 @default.
• W4384663359 creator A5064286490 @default.
• W4384663359 creator A5065625930 @default.
• W4384663359 creator A5076177073 @default.
• W4384663359 date "2023-07-19" @default.
• W4384663359 modified "2023-10-15" @default.
• W4384663359 title "Melatonin for migraine prevention in children and adolescents: A randomized, double‐blind, placebo‐controlled trial after single‐blind placebo lead‐in" @default.
• W4384663359 cites W2011239878 @default.
• W4384663359 cites W2026819672 @default.
• W4384663359 cites W2127246721 @default.
• W4384663359 cites W2139425168 @default.
• W4384663359 cites W2146590936 @default.
• W4384663359 cites W2347737266 @default.
• W4384663359 cites W2462694535 @default.
• W4384663359 cites W2540692073 @default.
• W4384663359 cites W2573837467 @default.
• W4384663359 cites W2609404357 @default.
• W4384663359 cites W2769724041 @default.
• W4384663359 cites W2975549399 @default.
• W4384663359 cites W3195889565 @default.
• W4384663359 cites W4223521545 @default.
• W4384663359 doi "https://doi.org/10.1111/head.14600" @default.
• W4384663359 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37466211" @default.
• W4384663359 hasPublicationYear "2023" @default.
• W4384663359 type Work @default.
• W4384663359 citedByCount "0" @default.
• W4384663359 crossrefType "journal-article" @default.
• W4384663359 hasAuthorship W4384663359A5003163742 @default.
• W4384663359 hasAuthorship W4384663359A5032639003 @default.
• W4384663359 hasAuthorship W4384663359A5034447689 @default.
• W4384663359 hasAuthorship W4384663359A5042770203 @default.
• W4384663359 hasAuthorship W4384663359A5052408475 @default.
• W4384663359 hasAuthorship W4384663359A5059512015 @default.
• W4384663359 hasAuthorship W4384663359A5064286490 @default.
• W4384663359 hasAuthorship W4384663359A5065625930 @default.
• W4384663359 hasAuthorship W4384663359A5076177073 @default.
• W4384663359 hasConcept C118552586 @default.
• W4384663359 hasConcept C126322002 @default.
• W4384663359 hasConcept C142724271 @default.
• W4384663359 hasConcept C16568411 @default.
• W4384663359 hasConcept C168563851 @default.
• W4384663359 hasConcept C1862650 @default.
• W4384663359 hasConcept C187212893 @default.
• W4384663359 hasConcept C202061045 @default.
• W4384663359 hasConcept C204243189 @default.
• W4384663359 hasConcept C204787440 @default.
• W4384663359 hasConcept C27081682 @default.
• W4384663359 hasConcept C2778182776 @default.
• W4384663359 hasConcept C2778541695 @default.
• W4384663359 hasConcept C2991744798 @default.
• W4384663359 hasConcept C42219234 @default.
• W4384663359 hasConcept C71924100 @default.
• W4384663359 hasConceptScore W4384663359C118552586 @default.
• W4384663359 hasConceptScore W4384663359C126322002 @default.
• W4384663359 hasConceptScore W4384663359C142724271 @default.
• W4384663359 hasConceptScore W4384663359C16568411 @default.
• W4384663359 hasConceptScore W4384663359C168563851 @default.
• W4384663359 hasConceptScore W4384663359C1862650 @default.
• W4384663359 hasConceptScore W4384663359C187212893 @default.
• W4384663359 hasConceptScore W4384663359C202061045 @default.
• W4384663359 hasConceptScore W4384663359C204243189 @default.
• W4384663359 hasConceptScore W4384663359C204787440 @default.
• W4384663359 hasConceptScore W4384663359C27081682 @default.
• W4384663359 hasConceptScore W4384663359C2778182776 @default.
• W4384663359 hasConceptScore W4384663359C2778541695 @default.
• W4384663359 hasConceptScore W4384663359C2991744798 @default.
• W4384663359 hasConceptScore W4384663359C42219234 @default.
• W4384663359 hasConceptScore W4384663359C71924100 @default.
• W4384663359 hasFunder F4320337951 @default.
• W4384663359 hasIssue "9" @default.
• W4384663359 hasLocation W43846633591 @default.
• W4384663359 hasLocation W43846633592 @default.
• W4384663359 hasOpenAccess W4384663359 @default.
• W4384663359 hasPrimaryLocation W43846633591 @default.
• W4384663359 hasRelatedWork W2065493489 @default.
• W4384663359 hasRelatedWork W2146466045 @default.
• W4384663359 hasRelatedWork W2417747790 @default.
• W4384663359 hasRelatedWork W2512623546 @default.
• W4384663359 hasRelatedWork W3034234392 @default.
• W4384663359 hasRelatedWork W3173892038 @default.
• W4384663359 hasRelatedWork W4205506075 @default.
• W4384663359 hasRelatedWork W4206035163 @default.
• W4384663359 hasRelatedWork W4229964879 @default.
• W4384663359 hasRelatedWork W4242840832 @default.
• W4384663359 hasVolume "63" @default.
• W4384663359 isParatext "false" @default.
• W4384663359 isRetracted "false" @default.
• W4384663359 workType "article" @default.